-
Cell Senescence β-Galactosidase Staining Kit Guide
2026-09-10
Turn growth arrest and inflammatory stress into a visible, quantifiable senescence readout with an X-gal workflow built for cultured cells and frozen tissue. K2185 is especially useful for macrophage infection models, senolytic screening, and mechanistic studies that pair SA-β-Gal with metabolic or cytokine measurements.
-
A-1331852: Precision BCL-XL Workflows
2026-09-09
A-1331852 is a potent, selective BCL-XL inhibitor for mapping apoptotic dependence, validating BCL-XL–BIM complex disruption, and designing senescence-focused cancer research assays. This guide converts its preclinical profile into practical workflows, controls, comparison strategies, and troubleshooting steps.
-
3-Bromopyruvate Reverses Cetuximab Resistance
2026-09-09
This 2023 Cancer Gene Therapy study shows that combining 3-bromopyruvate with cetuximab can suppress cetuximab-resistant colorectal cancer models through coordinated ferroptosis, autophagy, and apoptosis. The work identifies FOXO3a-dependent signaling as a mechanistic link between metabolic stress and multiple regulated cell-death programs, while offering a useful framework for pathway-dissection experiments.
-
saRNA Influenza Vaccines: Immunogenicity and Dose Sparing
2026-09-08
The reference study shows that self-amplifying RNA can overcome the weak influenza B responses observed with conventional mRNA vaccination in mice. At a low dose, trivalent saRNA produced durable antibodies and complete protection against influenza B challenge, supporting platform selection as an important determinant of subtype coverage and dose-sparing performance.
-
EZ Cap™ Cas9 mRNA (5-moUTP) in Neurobiology
2026-09-08
EZ Cap™ Cas9 mRNA (5-moUTP) enables transient CRISPR-Cas9 genome editing for mechanistic neurobiology. This article presents a decision framework for connecting Fyn–Stat3 pathway perturbation with cell-specific, temporal, and orthogonal assay readouts.
-
Clozapine Workflows for Schizophrenia Research
2026-09-07
Clozapine provides a practical pharmacological benchmark for receptor profiling, ERK1/2 signaling activation, and neurotoxicity experiments. Its distinctive receptor breadth also makes it useful for testing how drug-based modulation compares with targeted magnetic stimulation in preclinical schizophrenia research.
-
circRHOBTB3–NONO–MAOA Axis in Metastatic Prostate Cancer
2026-09-07
The reference study identifies circRHOBTB3 as a prostate cancer suppressor that limits NONO-dependent MAOA transcription by retaining NONO in the cytoplasm. Its integrated sequencing, molecular, cellular, and in vivo experiments connect circRNA biogenesis with metastatic progression and suggest a biomarker framework for advanced prostate cancer research.
-
CCG-1423: Separating RhoA Signaling Arms
2026-09-05
CCG-1423 is a research-focused RhoA inhibitor that helps distinguish MRTF-A nuclear import from the ROCK1-dependent cytoskeletal arm of RhoA signaling. This article translates that distinction into assay design for cancer research, apoptosis studies, and carefully controlled barrier models.
-
AEBSF.HCl: Serine Protease Inhibition Guide
2026-09-04
AEBSF.HCl, also called 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, is an irreversible broad-spectrum serine protease inhibitor for biochemical, cellular, and animal research. Reported applications include inhibition of amyloid-beta production, protease inhibition in leukemic cell lysis, and studies of APP cleavage, but the compound should not be treated as a general inhibitor of lysosomal cathepsins or as a proven necroptosis blocker.
-
HDAC Inhibitors Enhance Oncolytic HSV in Meningioma
2026-09-04
Kawamura and colleagues showed that histone deacetylase inhibition can increase the infectability, intratumoral spread, and antitumor activity of oncolytic herpes simplex virus in malignant meningioma models. The findings identify a rational combination strategy in which epigenetic modulation improves viral therapy at low viral input, while transcriptomic data point to altered mRNA processing and splicing as a possible mechanistic basis.
-
Deferoxamine mesylate in Iron and Hypoxia Assays
2026-09-03
Deferoxamine mesylate gives researchers a controllable way to reduce labile iron, probe ferroptosis, and induce HIF-1α stabilization. This guide translates those properties into practical cancer, oxidative-stress, and wound-healing workflows with assay-specific controls and troubleshooting.
-
Firefly Luciferase mRNA: From Signal to Strategy
2026-09-03
Firefly Luciferase mRNA is more than a convenient reporter: it can function as a mechanistic probe for translation, delivery, formulation stability, and freeze–thaw stress. This thought-leadership guide connects ARCA capping and 5-methoxyuridine chemistry with LNP development, experimental validation, and translational decision-making.
-
D-Luciferin sodium salt: Assay Reliability
2026-09-02
Learn how D-Luciferin sodium salt, SKU B8311, supports controlled firefly luciferase readouts for cell viability, metabolism, and oncology imaging workflows. The article connects practical preparation, CAR-macrophage research, and interpretation controls to improve confidence in ATP-dependent bioluminescence assays.
-
Hesperadin: Aurora B Kinase Inhibitor Guide
2026-09-02
Hesperadin is an ATP-competitive Aurora B kinase inhibitor that suppresses histone H3 Ser-10 phosphorylation and produces measurable mitotic defects. Its biochemical, cellular, and formulation properties support Hesperadin for cell-cycle research, while checkpoint-complex studies require careful separation of Aurora B effects from Plk1–p31comet regulation.
-
Mc-Val-Cit-PABC-PNP: ADC Workflow Guide
2026-09-01
Mc-Val-Cit-PABC-PNP is a cathepsin B-cleavable ADC peptide linker for constructing conjugates designed to release payloads after lysosomal protease cleavage. It is suited to controlled antibody-drug conjugate synthesis workflows using compatible organic solvent handling, but is not intended for aqueous formulation, diagnostic testing, or medical and therapeutic use.